10-Q: Neuronetics Reports Q1 2024 Results: Revenue Up, Losses Narrow

Neuronetics saw a 12% increase in revenue and a reduction in net losses in the first quarter of 2024 compared to the same period last year.

Summary

• Neuronetics reported a revenue of $17.4 million for the three months ended March 31, 2024, a 12% increase compared to $15.5 million in the same period of 2023.
• The company's net loss decreased to $7.9 million for the quarter, compared to a net loss of $10.5 million in the first quarter of 2023.
• U.S. revenue increased by 12%, driven by a rise in treatment session sales, while international revenue saw an 8% increase.
• Treatment session revenue in the U.S. grew by 22%, reaching $13.0 million, due to an increase in treatment sessions sold from 158,742 to 210,737.
• The company's gross margin improved to 75.1% from 73.3% in the prior year quarter.
• Neuronetics had $47.7 million in cash and cash equivalents as of March 31, 2024, with $60.0 million in borrowings outstanding under its credit facility.
• The company believes its current cash and anticipated revenues are sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and loss reduction, but the company is still operating at a loss and has significant debt. The outlook is cautiously optimistic, with management expressing confidence in the company's ability to fund operations for the next 12 months.

Positives

• Revenue increased by 12% year-over-year, indicating strong sales growth.
• Net losses decreased by 25% year-over-year, showing improved financial performance.
• Gross margin improved to 75.1%, reflecting better cost management and pricing.
• U.S. treatment session revenue increased by 22%, demonstrating strong demand for the company's services.
• The company believes it has sufficient cash to fund operations for at least the next 12 months.

Negatives

• The company continues to operate at a loss, with a net loss of $7.9 million for the quarter.
• U.S. NeuroStar Advanced Therapy System revenue decreased by 14%, indicating a potential slowdown in capital equipment sales.
• The company has a significant accumulated deficit of $384.0 million.
• The company has $60.0 million in borrowings outstanding under its credit facility.

Risks

• The company has a history of operating losses and expects to continue incurring losses in the near term.
• The company's revenue is concentrated among a small number of customers, with one customer accounting for more than 10% of revenue.
• The company is subject to risks related to competition, product defects, and regulatory changes.
• The company's ability to achieve profitability depends on its ability to increase sales and manage costs effectively.
• The company's credit facility has financial covenants that it must comply with, and any non-compliance could have a material adverse effect.

Future Outlook

Management believes that the company's cash and cash equivalents as of March 31, 2024 and anticipated revenues from sales of its products are sufficient to fund the company's operations for at least the next 12 months from the issuance of these financial statements. The company expects to continue to incur losses for the next several years as it invests in its commercial organization to support its planned sales growth and while continuing to invest in its pipeline indications.

Management Comments

• Management believes that the company's cash and cash equivalents as of March 31, 2024 and anticipated revenues from sales of its products are sufficient to fund the company's operations for at least the next 12 months.
• Management anticipates that its operating losses will lessen in the near term as the company adjusts its sales and marketing initiatives, research and development activities and other corporate initiatives.

Industry Context

Neuronetics operates in the medical technology sector, specifically focusing on neurohealth disorders. The company's NeuroStar system competes with other TMS therapies and traditional treatments for depression and OCD. The increase in treatment session revenue suggests a growing adoption of TMS therapy, while the decrease in system sales may indicate a shift in customer purchasing patterns or increased competition in the capital equipment market.

Comparison to Industry Standards

• Neuronetics' gross margin of 75.1% is relatively high compared to some medical device companies, but it is important to compare this to companies with similar business models, such as those that sell both capital equipment and recurring consumables.
• For example, companies like InMode (INMD) and Cutera (CUTR) also sell capital equipment and consumables, and their gross margins can vary depending on product mix and pricing strategies.
• Neuronetics' revenue growth of 12% is a positive sign, but it is important to compare this to the growth rates of other companies in the medical technology sector, particularly those focused on mental health treatments.
• The company's net loss of $7.9 million is not unusual for a growth-stage medical technology company, but it is important to monitor the company's progress towards profitability.
• Compared to other companies in the TMS space, Neuronetics claims to have the largest clinical data set, which could be a competitive advantage.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and reduced losses, but will be concerned about the ongoing losses and debt.
• Employees may be positively impacted by the company's growth and investment in its commercial organization.
• Customers will benefit from the company's continued investment in product development and support.
• Suppliers may see increased demand for their products as the company's sales grow.
• Creditors will be monitoring the company's financial performance and compliance with its credit facility.

Next Steps

• The company plans to continue investing in its commercial organization to support sales growth.
• The company plans to continue investing in research and development for additional indications.
• The company will continue to monitor macroeconomic impacts on its business.

Key Dates

Keywords

NeuroStar, TMS, Transcranial Magnetic Stimulation, Major Depressive Disorder, MDD, Treatment Sessions, Medical Technology, Neurohealth, Mental Health, Revenue, Gross Margin, Net Loss